Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
Status:
Completed
Trial end date:
2019-08-14
Target enrollment:
Participant gender:
Summary
Primary objective:
To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe
atopic dermatitis (AD).
Secondary objectives:
To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health
related quality of life compared with placebo.
Maintenance objective:
To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared
to placebo for subjects achieving clinical response at Week 16.